Shares in Paion AG surged more than 40 percent Thursday on news that its fast-acting anesthetic remimazolam hit the primary endpoint of a Phase II/III trial conducted by its Japanese partner, Osaka-based Ono Pharmaceutical Co. Ltd., and demonstrated a better cardiovascular safety profile than a widely used control drug.